886496-62-4 Usage
Uses
Used in Pharmaceutical Industry:
3-Chloro-5-fluoro-benzoyl chloride is used as a key intermediate in the synthesis of 3,6-disubstituted-1,2,4,5-tetrazine derivatives. These derivatives have potential applications as antitumor agents, making 3-CHLORO-5-FLUOROBENZOYL CHLORIDE an important component in the development of new cancer treatments.
Used in Organic Synthesis:
As a building block, 3-chloro-5-fluoro-benzoyl chloride is utilized in various organic synthesis processes to create a range of chemical compounds. Its unique structure allows for the formation of diverse molecules with potential applications in different fields, such as materials science and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 886496-62-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,4,9 and 6 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 886496-62:
(8*8)+(7*8)+(6*6)+(5*4)+(4*9)+(3*6)+(2*6)+(1*2)=244
244 % 10 = 4
So 886496-62-4 is a valid CAS Registry Number.
886496-62-4Relevant academic research and scientific papers
N-(Substituted sulfonyl)benzamide derivative and preparation method and pharmaceutical application thereof
-
Paragraph 0374; 0376-0379, (2019/04/17)
The invention relates to an N-(substituted sulfonyl)benzamide derivative and preparation method and pharmaceutical application thereof, in particular to an N-(substituted sulfonyl)benzamide derivativeshown as general formula (I), preparation method thereof, medicinal salts of the derivative, and their application as therapeutics, especially as Nav1.7 inhibitors, wherein substituents in the general formula (I) shown in the description are defined the same as in the description.
Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
-
, (2008/06/13)
The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
